Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate cardiovascular risk factors, clinical characteristics, and outcomes in adult patients attending an outpatient cardiology clinic. The research focuses on identifying predictors of adverse cardiovascular events, optimizing risk stratification, and improving preventive strategies in routine clinical practice. Data will be collected from patients receiving standard cardiology care without altering their treatment. The results are expected to contribute to better understanding of cardiovascular risk profiles and to support improvements in clinical decision-making and patient management.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Structured Clinical Management | Experimental | Participants receive structured clinical follow-up with periodic assessment of cardiovascular risk factors and adjustment of pharmacological and lifestyle management according to current clinical guidelines over a 120-day follow-up period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Structured Cardiovascular Risk Management | Other | Protocol-based clinical management including periodic evaluation and adjustment of antihypertensive, lipid-lowering, antidiabetic, and lifestyle interventions according to routine clinical practice guidelines. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in systolic blood pressure | Change in systolic blood pressure (mmHg) measured under standardized conditions to evaluate the effect of structured clinical and pharmacological cardiovascular risk management. | Baseline to 90 days |
| Measure | Description | Time Frame |
|---|---|---|
| Change in diastolic blood pressure | Evaluation of changes in diastolic blood pressure following structured clinical and pharmacological management. | Baseline to 90 days |
| Change in LDL cholesterol |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julio César Núñez Farías, MD, MSc (Cardiology) | Contact | +56965860130 | llaillai@yahoo.es |
| Name | Affiliation | Role |
|---|---|---|
| José Abellán Alemán, MD, PhD | Universidad Católica San Antonio de Murcia | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CDIEM Medical Center - Outpatient Cardiology Clinic | Recruiting | Santiago | Santiago Metropolitan | Chile |
Individual participant data will not be shared due to privacy regulations and institutional data protection policies. De-identified aggregated results will be available through scientific publication.
Not provided
Not provided
Not provided
Not provided
Not provided
Participants receive structured clinical follow-up with periodic evaluation and adjustment of standard pharmacological therapy under routine clinical practice using a before-and-after design.
Not provided
Not provided
Not provided
Not provided
Evaluation of changes in LDL cholesterol measured during routine laboratory assessment after structured cardiovascular risk management.
| Baseline to 90 days |
| Change in HbA1c | Evaluation of changes in glycated hemoglobin (HbA1c) following structured cardiovascular risk management. | Baseline to 90 days |
| Change in body weight | Evaluation of changes in body weight following lifestyle counseling and structured cardiovascular risk management. | Baseline to 90 days |
| Change in renal function (eGFR) | Evaluation of changes in renal function assessed by estimated glomerular filtration rate following structured cardiovascular risk management. | Baseline to 90 days |
| Change in HDL cholesterol | Evaluation of changes in HDL cholesterol measured during routine laboratory assessment after structured cardiovascular risk management. | Baseline to 90 days |
| Change in triglycerides | Evaluation of changes in triglyceride levels measured during routine laboratory assessment after structured cardiovascular risk management. | Baseline to 90 days |
| Change in total cholesterol | Evaluation of changes in total cholesterol measured during routine laboratory assessment after structured cardiovascular risk management. | Baseline to 90 days |
| Change in fasting plasma glucose | Evaluation of changes in fasting plasma glucose following structured cardiovascular risk management. | Baseline to 90 days |
| Change in body mass index | Evaluation of changes in body mass index following lifestyle counseling and structured cardiovascular risk management. | Baseline to 90 days |
| Change in microalbuminuria | Evaluation of changes in urinary albumin excretion to assess microalbuminuria during follow-up after structured cardiovascular risk management. | Baseline to 90 days |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D050171 | Dyslipidemias |
| D003924 | Diabetes Mellitus, Type 2 |
| D009765 | Obesity |
| D050177 | Overweight |
| D064424 | Tobacco Use |
| D055118 | Medication Adherence |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D004700 | Endocrine System Diseases |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |
| D010349 | Patient Compliance |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
Not provided
Not provided